SCHEMBL910003

SCHEMBL910003

COc1ccc2c(c1OS(C)(=O)=O)CN1CCc3cc4c(cc3C1C2)OCO4

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 12/20 0.80
DRD1 P21728 8/20 0.80
DRD2 P14416 4/20 0.80
CYP1A2 P05177 2/20 0.80
CYP3A4 P08684 2/20 0.80
CYP2D6 P10635 2/20 0.80
CYP2C19 P33261 2/20 0.80
DRD4 P21917 2/20 0.80
DRD5 P21918 2/20 0.80
DRD3 P35462 2/20 0.80
LMNA P02545 1/20 0.80
ADRA1A P35348 1/20 0.80
MEN1 O00255 1/20 0.80
KMT2A Q03164 1/20 0.80
HTR1A P08908 2/20 0.67
ALOX15 P16050 1/20 0.67
HIF1A Q16665 1/20 0.67
HSD17B10 Q99714 1/20 0.67
KDM4E B2RXH2 1/20 0.67
GAA P10253 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29999635 1.00 F3 (0.80) F3DRD1DRD2CYP1A2CYP3A4
SCHEMBL29999816 0.89 F3 (0.72) F3DRD1DRD2CYP1A2CYP3A4
SCHEMBL910294 0.89 F3 (0.72) F3DRD1DRD2CYP1A2CYP3A4
SCHEMBL2742658 0.89 F3 (0.75) F3DRD1DRD2CYP1A2CYP3A4
Tetrahydroberberine SCHEMBL2786492 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4
Tetrahydroberberine SCHEMBL30484836 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4
Tetrahydroberberine SCHEMBL30302597 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4
Canadine SCHEMBL29365824 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4
Tetrahydroberberine SCHEMBL232164 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4
Canadine SCHEMBL432394 0.89 F3 (1.00) F3DRD1DRD2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY CVI PHARMACEUTICALS LIMITED (KY) 2022-12-08 US disclosed
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY CVI PHARMACEUTICALS LIMITED (KY) 2022-12-08 US disclosed
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8710071-B2 Compounds, compositions and methods for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-04-29 US disclosed
US-8710071-B2 Compounds, compositions and methods for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-04-29 US disclosed
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2012-01-05 US disclosed
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2012-01-05 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-8003795-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2011-08-23 US disclosed
US-8003795-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2011-08-23 US disclosed
US-8003795-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2011-08-23 US disclosed
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same CVI PHARMACEUTICALS LIMITED (KY) 2011-01-13 US disclosed
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same CVI PHARMACEUTICALS LIMITED (KY) 2011-01-13 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same LIPC, LDLR, PCSK9 F3 1777/4885DRD1 4873/4885DRD2 4863/4885
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY LIPC, FABP1, CPT1A F3 1928/4885DRD1 4727/4885DRD2 4557/4885
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, LDLR, PCSK9 F3 2027/4885DRD1 4858/4885DRD2 4824/4885
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS LIPC, LIPE, BCHE F3 2828/4885DRD1 465/4885DRD2 139/4885
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, BCHE, LIPE F3 2601/4885DRD1 553/4885DRD2 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.